Sort by
Refine Your Search
-
, at one of Europe’s highest-ranked technical universities. Responsibilities and qualifications Who we're looking for We are seeking passionate physicists or engineers with a strong interest in quantum
-
Morten Kjaergaard. Who are we looking for? We are looking for motivated young physicists eager to tackle the formidable challenges of realizing fault-tolerant quantum computing from fresh and innovative
-
the ambitions to accelerate the detection and optimization of sustainable chemical approaches through the development of novel reactions and advanced analytics using state of the art high-field and hyperpolarized
-
of tissue plasticities in diet-induced obesity and regression. For the current project Unlocking the Deep GPCRome for Accelerated Fibrosis Resolution we seek a molecular and cell biologist or similar with
-
of code to utilize GPU-acceleration on DTU’s high-performance computing cluster or other HPC systems. You will also analyze realistic physical implementations of the architectures you explore, with a
-
techniques (e.g., HR-TEM, HR-STEM, 4D-STEM, iDPC, ptychography) and their application to challenging hybrid materials. Curiosity about how ML/AI-driven data science can accelerate discovery and innovation in
-
for accelerating characterisation and “state of health” monitoring. Testing of solid oxide cells under different operation conditions and microstructural characterisation after tests to identify degradation
-
methodologies for accelerating the green transition by activating the demand-side flexibility. In addition, you will become part of a European network of 15 PhD students and their supervisors funded under
-
passionate, curious, and driven individual, committed to accelerating the green transition by advancing autonomous solutions for wind power operations. You thrive on solving complex problems, ask bold and
-
sciences and advancing vaccine development. NIVI-R conducts scientific research, while NIVI-D works to quickly turn that research into new vaccine candidates. NIVI-D accelerates clinical trials (phases 1 and